title: Selective formation of covalent protein heterodimers with an unnatural amino acid.
abstract: We report a strategy for the generation of heterodimeric protein conjugates using an unnatural amino acid with orthogonal reactivity. This paper addresses the challenges of site-specificity and homogeneity with respect to the synthesis of bivalent proteins and antibody-drug conjugates. There are numerous antibody-drug conjugates in preclinical and clinical development, yet these are based either on nonspecific lysine coupling chemistry or on disulfide modification made difficult by the large number of cysteines in antibodies. Here, we describe a recombinant approach that can be used to rapidly generate a variety of constructs with defined conjugation sites. Moreover, this methodology results in homogeneous antibody conjugates whose biological, physical, and pharmacological properties can be quantitatively assessed and subsequently optimized. As proof of concept, we have generated anti-Her2 Fab-Saporin conjugates that demonstrate excellent potency in vitro.
authors: Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
authors: Benjamin M
authors: BM
authors: Hutchins
authors: Stephanie A
authors: SA
authors: Kazane
authors: Karin
authors: K
authors: Staflin
authors: Jane S
authors: JS
authors: Forsyth
authors: Brunhilde
authors: B
authors: Felding-Habermann
authors: Vaughn V
authors: VV
authors: Smider
authors: Peter G
authors: PG
authors: Schultz
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry* / Q000276:immunology / Q000633:toxicity; D045744:Cell Line, Tumor; D019281:Dimerization; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D000922:Immunotoxins / Q000737:chemistry* / Q000276:immunology / Q000633:toxicity; D008301:Maleimides / Q000737:chemistry; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000737:chemistry; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D054789:Ribosome Inactivating Proteins, Type 1 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D000076985:Saporins; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D007140:Immunoglobulin Fab Fragments; D000922:Immunotoxins; D008301:Maleimides; D010649:Phenylalanine; D018719:Erb-b2 Receptor Tyrosine Kinases; D011994:Recombinant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins; D000068878:Trastuzumab; C043592:maleimide